Oruka Therapeutics, Inc. (ORKA) stock
ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
$95.74−0.58 (-0.60%)
Close on Nov 18, 2026Market cap $6.34BP/E –Yield –
Oruka Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Oruka Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$155.08M. For fiscal 2025 it was -$122.05M. The highest annual figure on record is -$4.32M in fiscal 2012.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$122.05M | – |
| FY2023 | Dec 31, 2023 | -$7.30M | – |
| FY2022 | Dec 31, 2022 | -$10.60M | – |
| FY2021 | Dec 31, 2021 | -$19.34M | – |
| FY2020 | Dec 31, 2020 | -$9.77M | – |
| FY2019 | Dec 31, 2019 | -$5.81M | – |
| FY2018 | Dec 31, 2018 | -$8.12M | – |
| FY2017 | Dec 31, 2017 | -$18.71M | – |
| FY2016 | Dec 31, 2016 | -$16.61M | – |
| FY2015 | Dec 31, 2015 | -$11.46M | – |
| FY2014 | Dec 31, 2014 | -$9.69M | – |
| FY2013 | Dec 31, 2013 | -$6.94M | – |
| FY2012 | Dec 31, 2012 | -$4.32M | – |
| FY2011 | Dec 31, 2011 | -$7.36M | – |
| FY2010 | Dec 31, 2010 | -$9.18M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$50.11M | – |
| Q1 FY2026 | Mar 31, 2026 | -$36.43M | – |
| Q4 FY2025 | Dec 31, 2025 | -$34.43M | – |
| Q3 FY2025 | Sep 30, 2025 | -$34.11M | – |
| Q2 FY2025 | Jun 30, 2025 | -$28.43M | – |
| Q1 FY2025 | Mar 31, 2025 | -$25.09M | – |
| Q3 FY2024 | Sep 30, 2024 | -$29.45M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.49M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.59M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.94M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.97M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.80M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.55M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.55M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.22M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.28M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.68M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.72M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.84M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.10M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.13M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.34M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.28M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.25M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.51M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.78M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.53M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.66M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.16M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.77M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.30M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.48M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.56M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.38M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.29M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.71M | – |
| Q2 FY2016 | Jun 30, 2016 | -$3.94M | – |
See a number that looks wrong?